1. Pink Sheet
  2. >>Drug Safety

Smartphone Apps Appropriate For OTC Product Instructions – Consultant

 
• By Malcolm Spicer

“The present has passed us by” in using appropriate technology to provide consumers more information than on US Drug Facts labels, Pinney Associates’ Saul Shiffman says at CPHA conference.

FDA and the industry should get up to speed on incorporating smartphone apps to provide instructions on OTC drugs, says Saul Shiffman, senior scientific advisor for behavioral science, study design and analysis at pharma industry consultancy Pinney Associates.

Consumers' rampant and still increasing use of mobile apps for all manner of lifestyle, commerce and communications functions demonstrate that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

Makary’s Expert Panel Sparks Regulatory Action For Menopause Hormonal Therapy

 
• By Sarah Karlin-Smith

The requested changes to the class-wide warnings for hormone replacement therapies mark the first time one of Makary’s expert panels sparked regulatory action and could lead to broader scrutiny of their use.

Mifepristone: Judge Orders US FDA To Rethink Need For REMS Restrictions

 
• By Sue Sutter

A federal judge in Hawaii ruled the FDA failed to consider statutory factors relevant to the REMS and provide a “reasoned explanation” for its restrictive treatment of the drug, but remand could result in an agency determination that more extensive restrictions are needed.

UK MHRA’s AI Push Targets Predicting Harmful Drug Mixes And Helping Make Licensing Decisions

 
• By Anabel Costa-Ferreira

A new government-backed initiative is set to explore the use of AI in predicting side effects from drug interactions – a development that could cut costs and late-stage trial failures for pharma companies.

EMA Intensifies Push To Cut Non-Human Primate Use In Drug Trials

 
• By Eliza Slawther

Pharma companies are being asked for their views on a scientific reflection paper from the European Medicines Agency that discusses alternatives to using non-human primates in drug safety studies.

More from Pink Sheet

‘Why We Would Do It Again’ – Gilead & Roche On Pioneering Global Initiative For Manufacturing Change

Gilead and Roche reflect on their experiences with a global initiative that delivered aligned regulatory decisions through joint hybrid inspections and synchronized review of post-approval changes.

Novel Alzheimer’s Drug Blarcamesine Scheduled For High-Stakes EMA Oral Explanation

 
• By Neena Brizmohun

The EMA has scheduled oral explanation meetings this week for Anavex’s blarcamesine and three other products that are nearing the end of the regulatory review cycle. These meetings usually represent the final chance for sponsors to persuade the agency that their product merits approval.

Sponsored by

The British Pharmacopoeia: Setting standards that are trusted worldwide

In this exclusive article with Peter Crowley, Secretary and Scientific Director of the BP Commission, you’ll discover how the BP is preparing for its landmark 2026 edition while strengthening its influence as a global bridge between science, regulation, and industry.